TNGX · Company research
Tango Therapeutics, Inc. (TNGX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? - Yahoo Finance | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 20, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 | Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 16, 2026 | bullish | 1 | 1 |
| Why Tango Therapeutics Shares Are Falling Today - Quiver Quantitative | Why Tango Therapeutics Shares Are Falling Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics (TNGX) Ticks Higher: Shares Gain 1.51% to Close at $24.17 - Death Cross - https://www.siam.in/ | Tango Therapeutics (TNGX) Ticks Higher: Shares Gain 1.51% to Close at $24.17 - Death Cross https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 13, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares - Stock Titan | Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics Slides as Investors Appear to Pause Ahead of Next Clinical Catalysts - Quiver Quantitative | Tango Therapeutics Slides as Investors Appear to Pause Ahead of Next Clinical Catalysts Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 2, 2026 | neutral | 0 | 0.6 |
| Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan | Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan | Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run - Simply Wall Street | Tango Therapeutics (TNGX) Stock Looks Stretched After Its 236% Run Simply Wall Street | View source ↗ | Simply Wall Street | Sep 2, 2026 | neutral | 0 | 0.6 |
| TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - Zacks Investment Research | TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 12, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes - Simply Wall Street | Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
| Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? - Yahoo Finance | Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 2, 2026 | neutral | 0 | 0.6 |
| TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits | TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ Stocktwits | View source ↗ | Stocktwits | Jun 8, 2026 | neutral | 0 | 0.6 |
| TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits | TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside Stocktwits | View source ↗ | Stocktwits | May 15, 2026 | neutral | 0 | 0.6 |
| Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move - TIKR.com | Tango Therapeutics Stock Jumps 36% to a New High. Here’s What’s Driving the Move TIKR.com | View source ↗ | TIKR.com | Mar 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.